Duration of blood-pressure benefit from stem-cell infusion typically extends 6–18 months, with best outcomes observed when patients maintain lifestyle modification and continue at least low-dose antihypertensive therapy. Some patients experience gradual blood-pressure increase over 12–24 months, potentially requiring booster infusions or medication escalation. Durability depends on baseline endothelial reserve and ongoing cardiovascular risk-factor control (smoking, diet, exercise). Long-term freedom from antihypertensive drugs beyond 2 years post-infusion is rarely documented. Benefit often plateaus; MSCs may enhance rather than replace pharmacotherapy.
Arterial hypertension, or high blood pressure, arises from dysregulated vascular tone, altered endothelial function, sympathetic overactivity, and rarefaction of capillary beds — pathophysiological mechanisms studied across essential and secondary forms. Stem-cell research investigates whether placental mesenchymal stem cells and exosome preparations can restore endothelial homeostasis, promote vascular regeneration, suppress renin-angiotensin-aldosterone axis overactivity, and enhance nitric-oxide bioavailability. With 35 registered trials and 4 currently recruiting, the therapeutic rationale targets restoration of vascular biology rather than symptomatic blood-pressure control. Early clinical data suggest potential for reducing office and ambulatory blood pressure, improving microvascular function, and reducing left-ventricular hypertrophy when administered as adjuncts to standard antihypertensive therapy.
Am I a candidate? → · Arterial Hypertension: full overview → · Arterial Hypertension cost → · Cost →
Medically reviewed by StemCellAtlas’s editorial team with Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
StemCellAtlas is your guide to stem-cell therapy: what the evidence shows, which conditions are treated, and the real all-in cost by country — typically €3,000–8,000 with our partner Stem Plus (Sofia), Europe's lowest-cost EU destination, versus $15,000–35,000 in the US.
Get an honest assessment